Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 4/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25200960 | 0.83 | DDB1 (0.40) | DDB1CRBNSTSGPR119KDM4E | |
| SCHEMBL25219348 | 0.82 | DDB1 (0.40) | DDB1CRBNSTSGPR119KDM4E | |
| SCHEMBL25198469 | 0.82 | MET (0.43) | DDB1CRBNSTSGPR119KDM4E | |
| SCHEMBL20134927 | 0.81 | TLR8 (0.46) | DDB1CRBNGPR119KDM4EMAPT | |
| SCHEMBL25204297 | 0.81 | NSD2 (0.42) | DDB1CRBNSTSKDM4EMET | |
| SCHEMBL25210013 | 0.81 | GPR119 (0.45) | STSGPR119THRB | |
| SCHEMBL24779560 | 0.79 | TP53 (0.44) | DDB1CRBNSTSGPR119MAPT | |
| SCHEMBL31356908 | 0.79 | RECQL (0.43) | DDB1CRBNSTSGPR119MAPT | |
| SCHEMBL25197622 | 0.79 | DPP4 (0.44) | DDB1CRBNGPR119KDM4EMAPT | |
| SCHEMBL28549250 | 0.79 | CTSD (0.41) | DDB1CRBNGPR119KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4436961-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023097007-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097007-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | DDB1 151/4885CRBN 964/4885STS 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.